Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Treatment Response Biomarkers in Asthma and COPD

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Optimal Insertion Depth for Nasal Mid-Turbinate and Nasopharyngeal Swabs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Infrared Thermography as a Method of Verification in Raynaud's Phenomenon

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Four-Dimensional Flow MRI of Abdominal Veins: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Associations between Postprandial Gut Hormones and Markers of Bone Remodeling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26 weeks by copper-64-labeled [1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid]-D-Phe1, Tyr3-octreotate ([64Cu]DOTATATE) PET in 30 participants included in a substudy of a double-blind trial where persons with type 2 diabetes (T2D) were randomized to liraglutide (n = 15) or placebo (n = 15) for 26 weeks. Mean age (SD) was 66.4 (7.2) years, HbA1c 56.4 (9.2) mmol/mol and BMI 28.9 (4.6) kg/m2. Weight and HbA1c were significantly reduced by liraglutide vs. placebo (p ≤ 0.01). The [64Cu]DOTATATE uptake (mean standardized uptake values) was significantly reduced in the liraglutide-treated group (-0.11 [95% confidence interval -0.19 to -0.03], p = 0.01) and not changed significantly in the placebo group (-0.07 [-0.14 to 0.01], p = 0.08). The mean difference between groups did not reach significance (-0.04 [-0.15 to 0.07], p = 0.44). In conclusion, [64Cu]DOTATATE uptake was reduced in persons with T2D treated with liraglutide. However, the reduction compared to placebo did not reach statistical significance, perhaps due to limited power. A reduction in vascular inflammation with liraglutide could help explain the cardiovascular protection observed with GLP-1 RAs in outcome studies but warrants further and larger studies.

OriginalsprogEngelsk
Artikelnummer1431
TidsskriftDiagnostics
Vol/bind11
Udgave nummer8
ISSN2075-4418
DOI
StatusUdgivet - 8 aug. 2021

ID: 67683317